Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Kaur, G. Nagaraja, Hongying Zheng, D. Gizachew, M. Galukande, S. Krishnan, A. Asea (2012)
A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human diseaseBMC Cancer, 12
Hao Yin, Rosemary Kanasty, Ahmed Eltoukhy, A. Vegas, J. Dorkin, Daniel Anderson (2014)
Non-viral vectors for gene-based therapyNature Reviews Genetics, 15
Jinhua Wang, P. Ray, M. Sim, Xiao Zhou, K. Lu, Adrian Lee, Xin Lin, S. Bagaria, A. Giuliano, X. Cui (2012)
FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signalingOncogene, 31
Jie Wang, Ze Lu, M. Wientjes, J. Au (2010)
Delivery of siRNA Therapeutics: Barriers and CarriersThe AAPS Journal, 12
V. Seewaldt, Victoria Scott (2007)
Images in clinical medicine. Rapid progression of basal-type breast cancer.The New England journal of medicine, 356 13
Peng Hu, Xi Chen, Jing Sun, P. Bie, Leida Zhang (2014)
siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivoBioscience Reports, 35
P. Ray, Jinhua Wang, Y. Qu, M. Sim, J. Shamonki, S. Bagaria, X. Ye, Bing-ya Liu, D. Elashoff, D. Hoon, M. Walter, J. Martens, A. Richardson, A. Giuliano, X. Cui (2010)
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.Cancer research, 70 10
Diana Guzman-Villanueva, I. El-Sherbiny, D. Herrera-Ruiz, A. Vlassov, H. Smyth (2012)
Formulation approaches to short interfering RNA and MicroRNA: challenges and implications.Journal of pharmaceutical sciences, 101 11
Noga Bloushtain-Qimron, Jun Yao, E. Snyder, M. Shipitsin, Lauren Campbell, Sendurai Mani, Min Hu, Haiyan Chen, Vadim Ustyansky, J. Antosiewicz, P. Argani, M. Halushka, J. Thomson, P. Pharoah, A. Porgador, S. Sukumar, R. Parsons, A. Richardson, M. Stampfer, R. Gelman, T. Nikolskaya, Y. Nikolsky, K. Polyak (2008)
Cell type-specific DNA methylation patterns in the human breastProceedings of the National Academy of Sciences, 105
Jeffry Sander, J. Joung (2014)
CRISPR-Cas systems for editing, regulating and targeting genomesNature Biotechnology, 32
B. Kreike, Marieke Kouwenhove, H. Horlings, B. Weigelt, H. Peterse, H. Bartelink, M. Vijver (2007)
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomasBreast cancer research : BCR, 9
M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, Britta Dieckhoff, O. Janke, J. Endruschat, B. Durieux, N. Röder, K. Löffler, C. Lange, M. Fechtner, Kristin Moepert, G. Fisch, S. Dames, W. Arnold, K. Jochims, K. Giese, B. Wiedenmann, A. Scholz, J. Kaufmann (2008)
Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.Cancer research, 68 23
E. Rakha, J. Reis-Filho, I. Ellis (2008)
Basal-like breast cancer: a critical review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 15
D. Sarrió, S. Rodríguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, J. Palacios (2008)
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.Cancer research, 68 4
D. Biswas, J. Iglehart (2006)
Linkage between EGFR family receptors and nuclear factor kappaB (NF‐κB) signaling in breast cancerJournal of Cellular Physiology, 209
A. Bee, D. Brewer, C. Beesley, A. Dodson, S. Forootan, T. Dickinson, P. Gerard, B. Lane, S. Yao, C. Cooper, M. Djamgoz, C. Gosden, Y. Ke, C. Foster (2011)
siRNA Knockdown of Ribosomal Protein Gene RPL19 Abrogates the Aggressive Phenotype of Human Prostate CancerPLoS ONE, 6
VL Seewaldt, V Scott (2007)
Rapid progression of basal-type breast cancerNew Engl J Med, 356
N. Song, Yan Wang, X. Gu, Zong-you Chen, Liu-bin Shi (2013)
Effect of siRNA-mediated knockdown of eIF3c gene on survival of colon cancer cellsJournal of Zhejiang University SCIENCE B, 14
S. Badve, D. Dabbs, S. Schnitt, F. Baehner, T. Decker, V. Eusebi, S. Fox, S. Ichihara, J. Jacquemier, S. Lakhani, J. Palacios, E. Rakha, A. Richardson, F. Schmitt, P. Tan, G. Tse, B. Weigelt, I. Ellis, J. Reis-Filho (2011)
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologistsModern Pathology, 24
M. Smid, Yixin Wang, Yi Zhang, A. Sieuwerts, Jack Yu, J. Klijn, J. Foekens, J. Martens (2008)
Subtypes of breast cancer show preferential site of relapse.Cancer research, 68 9
Lin Li, Guo Hu (2015)
Pink1 protects cortical neurons from thapsigargin-induced oxidative stress and neuronal apoptosisBioscience Reports, 35
Mark Davis, J. Zuckerman, C. Choi, D. Seligson, A. Tolcher, C. Alabi, Y. Yen, J. Heidel, A. Ribas (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 464
Basal-like breast cancer (BLBC) is a malignant carcinoma with aggressive motility and rapid growth. Accounting for 15% of breast cancers, BLBC often exhibits a poor prognosis and tends to metastasize to the brain and lungs. Because most BLBC display a triple-negative phenotype (ER-, PR-, and HER2-), conventional cytotoxic chemotherapy remains the only treatment option despite poor success and high rate of relapse. The overexpression of the forkhead-box transcription factor C1 (FOXC1) was recently identified as a biomarker of BLBC. Increased expression of FOXC1 was linked to excessive mobility and growth of BLBC cell lines, suggesting FOXC1 as a therapeutic target. In this study, siRNA-mediated knockdown of FOXC1 was confirmed to decrease the proliferation rate, migration, and invasion in a model BLBC-like cell line (4T1). 4T1 and 4T1-∆FOXC1 cells lacking FOXC1 expression (generated by CRISPR/Cas9) were used to evaluate the effects of FOXC1 expression in an orthotopic murine model of BLBC. No statistically significant difference in tumor volume was observed between 4T1 and 4T1-∆FOXC1 tumors. Furthermore, tumors metastasized to the liver and lungs to a similar degree regardless of FOXC1 expression. These data suggest that, despite positive results in vitro, FOXC1 may not be a promising therapeutic target for BLBC.
Cancer Gene Therapy – Springer Journals
Published: Mar 6, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.